
Gaudium IVF Q1 Results FY27: Revenue Rs 19 crore, PAT Rs 1 Crore
Gaudium IVF Q1 results: Revenue Rs 19 crore (+9.05% YoY). PAT Rs 1 Cr (-43.20% YoY). GP Rs 1 crore. CMP Rs 125.74 (+2.00%).
Updated: 14 Aug 2026 • 10:56 am
Posted by:

Quick Answer
Gaudium IVF Q1 results for FY27, declared on August 13, 2026, show revenue of Rs 19 crore, up 9.05% year on year from Rs 17 crore. Net profit came in at Rs 1 crore, down 43.2% year on year on a consolidated basis. Gross profit stood at Rs 1 crore for the April to June 2026 quarter. The stock closed at Rs 125.74, up 2% on results day.
Gaudium IVF Q1 results for FY27 were declared on August 13, 2026, covering the April to June 2026 quarter. Revenue came in at Rs 19 crore, up 9.05% year on year from Rs 17 crore. Net profit stood at Rs 1 crore on a consolidated basis. Gross profit was Rs 1 crore for the quarter.
The Gaudium IVF Q1 results analysis below covers financial highlights, key business drivers, FY27 outlook, and investor risks. The Nifty Pharma index reflects the broader Healthcare and Fertility sector backdrop against which these results should be read.
Click Here – Get Free Investment Predictions
Gaudium IVF Q1 Results: Financial Highlights
| Metric | Q1 FY27 (Jun 26) | Q1 FY26 (Jun 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 19 Cr | Rs 17 Cr | +9.05% YoY |
| Gross Profit | Rs 1 Cr | Rs 4 Cr | -61.20% YoY |
| Net Profit (PAT) | Rs 1 Cr | Rs 3 Cr | -43.20% YoY |
Source: Company filing, August 13, 2026. Figures in Rs Crore. Consolidated basis.
Q1 FY27 Performance Analysis
Gaudium IVF Q1 results show revenue that expanded during the April to June 2026 period. Gross profit came under pressure, pointing to cost headwinds during the quarter. Net profit of Rs 1 crore reflects a healthy earnings trajectory.
A detailed look at Gaudium IVF Q1 results reveals that revenue grew 9.05% year on year, while the consolidated numbers offer a group-level view of the company. Analysts will focus on margin trajectory and the outlook for the remaining quarters of FY27.
Investors assessing these quarterly results should also track working capital trends, operating leverage, and management commentary on FY27 guidance. Subsequent quarterly disclosures will help validate whether the trends visible in this print continue.
Check Live Financials on the Univest Screener
Key Business Factors This Quarter
Patient Volume and Revenue Per Cycle — This was a key driver this quarter. Its positive contribution supported the quarterly revenue trajectory. Investors should track changes in this area in subsequent disclosures.
New Clinic Expansion — This had a direct bearing on gross margins during the April to June 2026 period. Pressure here contributed to the gross profit decline. Management's approach will shape margin outcomes in the quarters ahead.
Operating Efficiency — This factor shaped the overall operating environment this quarter. Monitoring its trajectory will help investors anticipate directional changes in the next quarterly update.
Dividend Details
No interim dividend was announced as part of the quarterly results declared on August 13, 2026 for Gaudium IVF. Companies in the Healthcare and Fertility sector typically declare dividends once a year alongside full-year results. Investors should monitor official BSE or NSE filings for any future payout updates.
FY27 Outlook for Gaudium IVF
Gaudium IVF Q1 results for FY27 establish a positive starting point for FY27. The Healthcare and Fertility sector broadly faces steady conditions heading into H2 FY27, providing context for interpreting the April to June quarter print.
Investors using these Q1 FY27 results as a base for full-year projections should monitor whether revenue momentum and margin improvement continue into Q2 and Q3. Management commentary on capacity, order book, and pricing will be important inputs for refining full-year estimates.
Gaudium IVF Stock Performance After Q1 Results
Gaudium IVF's share price closed up at Rs 125.74, up 2% on August 13, 2026, the day the Q1 FY27 results were announced. The market received the results constructively. Stock movements on results day reflect immediate sentiment and may not represent the long-term investment picture.
Investors can track live price data and financial details on NSE (nseindia.com) and BSE (bseindia.com). Always verify current prices and official filings before any investment decision.
Download the Univest iOS App or Univest Android App to track Gaudium IVF's live share price.
Key Risks to Watch After the Q1 Results
Regulatory Changes in IVF Sector
This risk could weigh on revenue or margins if it intensifies. Investors should track how management addresses this in upcoming quarterly disclosures.
Competition from Larger Hospital Groups
This represents a potential headwind for FY27. If it materialises, it could affect the earnings trajectory visible in recent quarterly numbers.
Capital Intensity
This structural risk is shared with peers in the Healthcare and Fertility space. It warrants monitoring as it can influence fair value and longer-term earnings potential.
Conclusion
Gaudium IVF Q1 results for FY27 highlight the challenges facing the company in the current environment. Net profit was under pressure year on year. The coming quarters will test whether recovery is underway. Investors reviewing Gaudium IVF Q1 results should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Gaudium IVF Q1 Results
What were Gaudium IVF Q1 results for FY27?
Ans. Gaudium IVF Q1 results for FY27 show revenue of Rs 19 crore, up 9.05% year on year from Rs 17 crore and net profit of Rs 1 crore on a consolidated basis. Declared August 13, 2026.
When were the Q1 FY27 results declared for Gaudium IVF?
Ans. The Q1 FY27 results for Gaudium IVF were declared on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was the revenue in Q1 FY27?
Ans. Revenue for the quarter was Rs 19 crore, up 9.05% year on year from Rs 17 crore. Refer to official BSE or NSE filings for complete financial data.
Did Gaudium IVF Q1 results include a dividend?
Ans. No interim dividend was included in the Q1 FY27 results announcement for Gaudium IVF. Dividends are typically declared with full-year results. Check official filings for updates.
How did the stock react to Q1 FY27 results?
Ans. The stock closed up at Rs 125.74, up 2% on August 13, 2026. Stock movements on results day reflect immediate sentiment and may not indicate long-term direction.
What are the key risks highlighted after Q1 FY27?
Ans. Key risks after Q1 FY27 include regulatory changes in ivf sector, competition from larger hospital groups, and capital intensity. Track quarterly disclosures for updates on how these evolve.
What is the FY27 outlook based on Q1 FY27 performance?
Ans. Based on Q1 FY27 performance, FY27 full-year results will depend on sustaining revenue growth and expanding margins. The Healthcare and Fertility sector environment and company execution will be the main drivers.
Where can I find the complete Q1 FY27 financial data for Gaudium IVF?
Ans. Gaudium IVF Q1 results are available on BSE (bseindia.com) and NSE (nseindia.com) filing portals. The Univest screener also provides a curated financial snapshot.
Recent Articles

Victoria Mills Q1 Results FY27: Net Profit Surges 63.2%, Revenue Rs 19 crore
14 August 2026

Guru Krupa Gems Q1 Results FY27: Revenue Rs 3 crore, Net Profit Rs 0.05 Crore
14 August 2026

PCS Q1 Results FY27: Revenue Rs 0.1 crore, Net Profit Rs 0.49 Crore
14 August 2026

FII Data Today for 13 August 2026: DIIs Net Buy Rs 4,353 Crore While FIIs Net Sell Rs 511 Crore as Domestic Institutions Support Indian Equities
14 August 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Victoria Mills Q1 Results FY27: Net Profit Surges 63.2%, Revenue Rs 19 crore
Guru Krupa Gems Q1 Results FY27: Revenue Rs 3 crore, Net Profit Rs 0.05 Crore
PCS Q1 Results FY27: Revenue Rs 0.1 crore, Net Profit Rs 0.49 Crore
FII Data Today for 13 August 2026: DIIs Net Buy Rs 4,353 Crore While FIIs Net Sell Rs 511 Crore as Domestic Institutions Support Indian Equities
Shree Rajasthan Q1 Results FY27: Revenue Rs 3 crore, Net Loss Rs 0.7 Crore on Standalone Basis

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





